Metformin (Glucophage) disrupts normal metabolism and causes lactic acidosis (automatically, by blocking the Cori cycle).
Original statement
أدوية مثل الجلوكوفاج والفورسيجا تعطّل العمليات الأيضية الطبيعية للجسم، وتتسبب في مضاعفات مثل الحماض اللاكتيكي أو الكيتوني.
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Metformin (Glucophage) disrupts normal metabolism and causes lactic acidosis (automatically, by blocking the Cori cycle).
Origin
- Source status
- Archive quote (no location given)
- Attribution
- Elawady (archive paraphrase; source video not given)
- Origin
- https://eltayebat.com/rule/oral-diabetes-drugs/
- Attribution uncertainty
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. 'Glucophage causes acidity in the blood' is found (5QU3gO-o0Mg). The mechanism 'by blocking the Cori cycle' was not checked verbatim.
- Claimed mechanism
Metformin inhibits hepatic gluconeogenesis from lactate (Cori cycle), so lactate accumulates.
- Claimed health effect
Lactic acidosis
- Population concerned
Metformin users
- Geographic restriction by Elawady
none found
Diverging source versions
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- الغيبوبات السكرية ؟! (Open source)
- Published
- 30 April 2025
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
بوديز وسكره مظبوط اه واحد بياخد جلوكوفاج عشان يخس او عيان عنده سكر وبياخد جلوكوفاج وسكر سكره عالي شويه ويخش بلاكتيك اسيدوزيس يبقى معنى كده يا باشا القصه مش قصه انسولين ومش قصه
Glucophage (metformin), taken for weight loss or for diabetes, can cause lactic acidosis even when blood sugar is normal or only slightly raised.
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live! الغيبوبة الكيتونية (Open source)
- Published
- 23 April 2025
- Timestamp
- 0:45:04 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
غيبوبه ده بس سكره مظبوط بس عنده حموضه في الدم الجلوكوفاج بيعملها يبقى سكر او سكره يوجوال ومعاه حموضه الجلوكفاج بيعملها يا باشا صح
...coma; his sugar is just right but he has acidity in the blood - Glucophage does that; so his sugar is usual and with it acidity - Glucophage does that, sir, right.
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! التراكمي عال و السكر واطيي (Open source)
- Published
- 5 October 2025
- Timestamp
- 1:36:54 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Close paraphrase of the metformin/acidosis part.
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Metformin causes lactic acidosis.
2. What is demonstrably correct?
Metformin lowers hepatic glucose production; in situations of severe kidney failure, shock or hypoxia it can accumulate, and labels advise caution. ADA 2026 advises considering holding metformin when oral intake cannot be maintained (I-INS-10).
3. What is wrong or exaggerated?
Cochrane: 'no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use'; upper limit 4.3 vs 5.4 cases per 100,000 patient-years for non-metformin; no difference in lactate levels (I-ODD-08). Metformin reduced all-cause mortality by 36% in overweight patients in UKPDS 34 (I-ODD-01) and was associated with lower mortality at 10 years (I-INS-02). The archive's own cited cohorts used metformin as the reference with the lowest risk (A-INS-08, A-ODD-07).
4. What remains unclear?
Exact incidence in people with advanced kidney disease.
5. Which studies support it?
Mechanism; label warnings.
6. Which studies contradict it?
7. What applies to Germany and Europe?
Metformin is first-line therapy in EU/German guidelines with eGFR-based dose limits.
8. What is known about Egypt?
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. What practical conclusion is appropriate?
Metformin-associated lactic acidosis is very rare and mostly linked to contraindicated situations. Metformin is one of the safest and best-studied diabetes drugs; B12 should be checked periodically (see C-ODD-07).
Assessment details
- Rationale for certainty of evidence
Mechanistic kernel (metformin reduces hepatic gluconeogenesis) and rare case reports, mainly in severe kidney failure, hypoxia or overdose, are real. A Cochrane review of 347 trials/cohorts (70,490 patient-years) found no case of lactic acidosis and no difference in lactate vs other drugs. The claim that metformin causes lactic acidosis 'automatically' is therefore false; 'can rarely contribute in contraindicated situations' would be correct.
- Source quality
Archive paraphrase plus own words.
- Regional transferability
Universal.
- Individual exceptions
Severe kidney impairment, shock, hypoxia, alcohol excess and contrast/surgery situations require dose adjustment or pausing.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Metformin has a theoretical risk of acid build-up in the blood, mainly in people with very poor kidney function or severe illness. A large review of more than 300 studies found no such cases in about 70,000 patient-years. In a long British study, metformin users lived longer. Doctors adjust or pause metformin when kidneys fail or during serious illness.
Studies on this claim
Studies supporting the claim (1)
-
ADA guideline 2026: blood sugar goals and emergencies
American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006Guideline / position statementindependent cross-checkfull text checked★ key studyMost adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Glycaemic goals, hypoglycaemia and hyperglycaemic crises
- How was the study done?
Clinical practice guideline (ADA Standards of Care 2026, Section 6)
- How many people, animals or samples were studied?
not applicable; People with diabetes
- What was actually found?
Individual targets; do not stop basal insulin when not eating.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Moderate targets and safety rules.
- What are the study's limitations?
US-centred; Partially read
- What does it say about Elawady's specific claim?
Supports C-INS-04, C-INS-11; contradicts C-FAST-01, C-FAST-03, C-DIAB-02.
- Do the results apply to Germany and Europe?
Consistent with EASD guidance.
- What can explicitly not be concluded from this study?
Not applicable.
No study in this group is marked as key.
Studies contradicting or limiting the claim (3)
-
Metformin and lactic acidosis: Cochrane review
Salpeter SR et al.. Cochrane Database Syst Rev 2010 · PMID 20393934 · DOI 10.1002/14651858.CD002967.pub4Systematic reviewindependent cross-checkabstract only checked★ key studyNo lactic acidosis cases in about 70,000 patient-years of metformin use.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Incidence of lactic acidosis and lactate levels with metformin
- How was the study done?
Cochrane systematic review of comparative trials and cohorts
- How many people, animals or samples were studied?
347 studies; 70,490 metformin vs 55,451 non-metformin patient-years; Type 2 diabetes in trials/cohorts >=1 month
- What was actually found?
No cases; no lactate difference.
- How large was the observed effect?
Upper limit 4.3/100,000 PY
- What do the results mean in everyday life?
Metformin acid build-up is extremely rare.
- What are the study's limitations?
Trials often excluded high-risk patients
- What does it say about Elawady's specific claim?
Contradicts C-ODD-01.
- Do the results apply to Germany and Europe?
International.
- What can explicitly not be concluded from this study?
Risk in severe kidney failure.
-
Metformin in overweight type 2 diabetes (UKPDS 34)
UKPDS Group. Lancet 1998 · PMID 9742977Randomised controlled trialindependent cross-checkabstract only checked★ key studyMetformin reduced deaths from any cause by about a third over 10 years.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Intensive control with metformin in overweight type 2 diabetes
- How was the study done?
RCT within UKPDS (UKPDS 34)
- How many people, animals or samples were studied?
753 (main comparison); Overweight newly diagnosed type 2 diabetes, mean age 53
- What was actually found?
Mortality -36%.
- How large was the observed effect?
RR reduction 36% (9-55)
- What do the results mean in everyday life?
Metformin is protective.
- What are the study's limitations?
Small arms; Open-label; Conflicting supplementary result
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
UK.
- What can explicitly not be concluded from this study?
Effects in non-overweight patients.
-
UKPDS legacy: 10 years after the trial
Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470Randomised controlled trialindependent cross-checkabstract only checked★ key studyPeople treated intensively early with sulfonylureas or insulin had 15% fewer heart attacks and 13% fewer deaths years later.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Do UKPDS benefits persist and do macrovascular effects emerge?
- How was the study done?
Post-trial monitoring of an RCT (UKPDS 80)
- How many people, animals or samples were studied?
4,209 randomised; 3,277 monitored; Newly diagnosed type 2 diabetes from UKPDS
- What was actually found?
Legacy reductions in MI and death.
- How large was the observed effect?
Death -13% (SU/insulin), -27% (metformin)
- What do the results mean in everyday life?
Early good control pays off for decades.
- What are the study's limitations?
Post-trial therapy not controlled; Questionnaire follow-up
- What does it say about Elawady's specific claim?
Contradicts C-INS-03, C-INS-05 and C-DIAB-01: early insulin/SU therapy reduced MI and death long-term.
- Do the results apply to Germany and Europe?
UK; directly relevant.
- What can explicitly not be concluded from this study?
Effects of extreme targets in late disease.
No study in this group is marked as key.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Metformin is first-line therapy in EU/German guidelines with eGFR-based dose limits.
Egypt
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
What applies in my country?
General scientific assessment
Mostly false Lactic acidosis from metformin is very rare and occurs mainly in contraindicated situations.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.. Salpeter SR et al.. Cochrane Database Syst Rev 2010 · PMID 20393934 · DOI 10.1002/14651858.CD002967.pub4
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742977
- 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470